How brain processes are rewired in Parkinson's disease

Published Date: 02 Mar 2023

Researchers from the University of Queensland have confirmed that genes associated with the risk of Parkinson's disease also contribute to the production of cellular debris in the brain.

Read Full News

Latest News

Exploring A Potential New Method to Evaluate CTE Progression in Living Patients Louie Pasculli, Shae Datta, MD

Shae Datta, MD, co-director of the NYU Concussion Center, explained new findings regarding potential CTE diagnosis in living patients.

Phase 4 Data Support Effectiveness of Deutetrabenazine in Managing Tardive Dyskinesia, Chorea Louie Pasculli

Real-world data from Teva Pharmaceuticals’ IMPACT-TD Registry showed that deutetrabenazine and its extended-release formulation led to significant reductions of involuntary movements and improved quality of life for adults with tardive dyskinesia.

Evaluating GLP-1 Receptor Agonist Semaglutide in Phase 3 Settings for Alzheimer Disease: The EVOKE Trials Isabella Ciccone, MPH

Topline results of the EVOKE and EVOKE+ studies of semaglutide will be presented at the 2025 Clinical Trials on Alzheimer’s Disease Conference, held December 1-4, in San Diego, California.

Insight the Future of Anti-Tau Drug Development for Alzheimer Disease Marco Meglio

Charles Bernick, MD, a staff neurologist at the Cleveland Clinic Lou Ruvo Center for Brain Health, commented on the scientific rationale, therapeutic strategies, and biomarker advances driving the next wave of anti-tau drug development in Alzheimer disease.

NeuroVoices: Christina Briscoe, MD, on Improving Timely and Effective Care for Infantile Epileptic Spasm Syndrome Marco Meglio

The pediatric epileptologist at Boston Children’s Hospital discussed national variability in treating infantile epileptic spasms syndrome and the evidence gaps that continue to shape clinical decision making.

GLP-1 Semaglutide Fails to Outperform Placebo in Phase 3 EVOKE Trial of Alzheimer Disease Isabella Ciccone, MPH

Results from the EVOKE and EVOKE+ phase 3 studies reported that oral semaglutide did not significantly reduce clinical progression in patients with early symptomatic Alzheimer disease.

Todays Updates

Standalone Traumatic Brain Injuries Rarely Lead to Chronic Traumatic Encephalopathy Development Enna Selmanovic, Louie Pasculli

Enna Selmanovic, a PhD candidate at Mount Sinai, spoke on a recently published study regarding the incidence of traumatic brain injury and the potential for long-term health issues with chronic traumatic encephalopathy.

Todays Updates

Standalone Traumatic Brain Injuries Rarely Lead to Chronic Traumatic Encephalopathy Development Enna Selmanovic, Louie Pasculli

Enna Selmanovic, a PhD candidate at Mount Sinai, spoke on a recently published study regarding the incidence of traumatic brain injury and the potential for long-term health issues with chronic traumatic encephalopathy.

Latest News

Shae Datta, MD, co-director of the NYU Concussion Center, explained new findings regarding potential CTE diagnosis in living patients.

Real-world data from Teva Pharmaceuticals’ IMPACT-TD Registry showed that deutetrabenazine and its extended-release formulation led to significant reductions of involuntary movements and improved quality of life for adults with tardive dyskinesia.

Topline results of the EVOKE and EVOKE+ studies of semaglutide will be presented at the 2025 Clinical Trials on Alzheimer’s Disease Conference, held December 1-4, in San Diego, California.

Charles Bernick, MD, a staff neurologist at the Cleveland Clinic Lou Ruvo Center for Brain Health, commented on the scientific rationale, therapeutic strategies, and biomarker advances driving the next wave of anti-tau drug development in Alzheimer disease.

The pediatric epileptologist at Boston Children’s Hospital discussed national variability in treating infantile epileptic spasms syndrome and the evidence gaps that continue to shape clinical decision making.

Results from the EVOKE and EVOKE+ phase 3 studies reported that oral semaglutide did not significantly reduce clinical progression in patients with early symptomatic Alzheimer disease.

News All Time

NeurologyLive® Brain Games: November 23, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neural network plasticity after stroke!

Multi-Arm Phase 2 Trial Fails to Show Efficacy for Cognitive Programs in Treating Long COVID Marco Meglio

A recent trial reveals that online cognitive training and other interventions are ineffective for treating long COVID cognitive symptoms, highlighting treatment challenges.

CAR-T Therapy KYV-101 Achieves Durable Response in Phase 2/3 KYSA-6 Trial of Myasthenia Gravis Marco Meglio

KYV-101 shows promising efficacy in treating generalized myasthenia gravis, offering hope for durable remission through innovative CAR T-cell therapy.

Reimagining Neuroscience Trials: Precision, Partnership, and Progress Marco Meglio, Daniel Mikol, MD, PhD

Daniel Mikol, MD, PhD, vice president of neuroscience development at AbbVie, discussed how precision tools, AI, and patient partnership are reshaping the design and execution of modern neuroscience clinical trials.

Expert Panel Publishes Revised Consensus Recommendations for Diagnosis and Management of NMOSD Isabella Ciccone, MPH

In a newly published study, researchers developed expert-driven, evidence-based, up-to-date consensus recommendations for managing neuromyelitis optica spectrum disorder in Saudi Arabia.

Treating Obstructive Sleep Apnea: Beyond CPAP and Toward Hypoglossal Nerve Stimulation Vaishal Shah, MD, MPH, FAASM, FAAP

Vaishal Shah, MD, MPH, FAASM, FAAP, center director of the Sleep Disorders Center at Cleveland Clinic, spoke on the changes in how obstructive sleep apnea is treated, moving away from CPAP to more novel approaches.

Building the Next Era of ALS Clinical Research and Trials Marco Meglio

Ryan Donaghy, MD, an assistant professor of neurology at Northwestern Medicine, discussed the evolving landscape of ALS clinical trials, including advances in biomarkers, genetics, and modern trial design.

Orexin Agents ORX750 and ORX142 Show Promising Early Phase 1 and 2 Data Marco Meglio

Centessa Pharmaceuticals reveals promising early-stage results for its orexin receptor 2 agonists, ORX750 and ORX142, targeting neurologic sleep disorders.

NeurologyLive® Friday 5 — November 14, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 14, 2025.

FDA Adds Boxed Warning, Narrows Indication for DMD Gene Therapy Isabella Ciccone, MPH

The agency has required a postmarketing observational study to monitor safety for at least 12 months following gene therapy treatment in patients with Duchenne muscular dystrophy.

Cladribine More Effective Than S1P Receptor Modulators in Treating Relapsing-Remitting MS, Study Shows Louie Pasculli

Cladribine shows superior efficacy over S1P modulators in reducing disability progression in treatment-naive relapsing-remitting MS patients.

NeurologyLive® Brain Games: November 16, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on CAR-T therapy for autoimmune neurologic diseases!

Elena Grebenciucova, MD, on Evolving Standards in NMOSD Diagnosis and Management Elena Grebenciucova, MD, Marco Meglio

The assistant professor of neurology at Northwestern University explained key diagnostic, therapeutic, and management considerations for clinicians caring for patients with NMOSD across diverse and evolving clinical scenarios.

This Week on NeurologyLive® — November 17, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Multidisciplinary Care Paths That Improve Neurosarcoidosis Management Spencer Hutto, MD, Marco Meglio

Spencer Hutto, MD, associate program director of the adult neurology residency at Emory University, outlined the key diagnostic nuances, treatment considerations, and emerging therapeutic strategies shaping modern neurosarcoidosis care.

Decoding the Circuitry That Stabilizes Memory Maps in the Hippocampus Marco Meglio

Jayeeta Basu, PhD, an assistant professor in the departments of Psychiatry and Neuroscience at NYU Langone, commented on how newly decoded entorhinal–hippocampal circuits stabilize memory maps during learning.

Recommended News For You

An Intimate Life of Medical Innovation and Charity.

Clinical trial could lead to new 'gold standard' test for prostate cancer detection

Reversing the toxic relationship with high doses of chemotherapy in oncology.

Early Identification of Ovarian Cancer; Allergy Medicine for NSCLC? Unfavorable Development for Anti-TIGIT Medication?

A BRAF V600E mutation-positive intrathoracic synovial sarcoma is reported by researchers.

With the use of a novel sequencing technique, pediatric bone marrow transplant mortality can be predicted by analyzing lung microbiomes.

New guidelines expand access to lung cancer screening, but gaps remain in reaching rural and uninsured populations

Recommended Articles For You

Understanding Dasatinib: A Promising Drug for Cancer Treatment  

HPV Infection Review: Epidemiology, Risks, and Therapeutic Advances for Clinicians 

Managing High Potassium Levels: A Comprehensive Guide to Veltassa  

Emicizumab in Infants with Severe Hemophilia A: HAVEN 7 Phase 3b Trial Insights 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Three Cycles of Chemo Noninferior to Six for Rare Childhood Eye Cancer

2.

AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns

3.

What Dolph Lundgren's journey from terminal diagnosis to 'cancer free' can tell us about cancer care

4.

Experts Discuss Groundbreaking Advances in EGFR-Mutant Lung Cancer

5.

Analysis of 2021 data shows new cancer diagnoses did not rebound as expected following pandemic

1.

Biologic Therapies for Cutaneous Immune-Related Adverse Events in the Era of Immune Checkpoint Inhibitors

2.

Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era

3.

The Importance of Early Detection in Skin Cancer: Why Regular Skin Exams Matter 

4.

The Growing Challenge of Haematological Malignancies in Older Adults

5.

Landmark Medical Oncology Trials Redefining Early Breast Cancer Management

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV

2.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV

3.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII

4.

Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases

5.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot